Perioperative blood transfusions and cancer recurrence.
This collective review addresses the issue of transfusion-induced immunosuppression as it relates to patients undergoing cancer surgery. Patients receiving perioperative blood transfusions have a significantly worse prognosis than patients undergoing cancer surgery without a perioperative transfusion. It is thought that this is because transfusions produce a nonspecific immunosuppression by increasing the number and/or activity of suppressor T lymphocytes, decreasing the number of natural killer cells, and inducing anti-idiotypic antibodies. This risk, particularly when considered with the other risks of transfusion such as hepatitis or the acquired immunodeficiency syndrome (AIDS), suggests that criteria for transfusion of these patients should be stringent and related to an unequivocal need for replenishment of RBCs.
D006801:Humans; D007108:Immune Tolerance; D009364:Neoplasm Recurrence, Local / Q000209:etiology* / Q000276:immunology; D009366:Neoplasm Seeding; D009369:Neoplasms / Q000276:immunology / Q000601:surgery*; D011300:Preoperative Care; D011379:Prognosis; D065227:Transfusion Reaction